Fol­low­ing in As­traZeneca’s car­bon-re­duced foot­steps, No­var­tis an­nounced new sus­tain­abil­i­ty tar­gets on Tues­day, which in­clude plans to neu­tral­ize sup­ply chain emis­sions in the next 10 years.

The Swiss phar­ma aims to be car­bon-neu­tral in its own op­er­a­tions by 2025, and across its sup­ply chain by 2030. To get there, it says it will re­duce ab­solute emis­sions by 35% across its val­ue chain, and fol­low a “dual strat­e­gy” to de­crease en­er­gy and fu­el con­sump­tion, im­prove ef­fi­cien­cy and adopt re­new­able en­er­gy sources. It au­dit­ed all ma­jor sites for po­ten­tial im­prove­ments.

“We have a long­stand­ing, com­pre­hen­sive en­er­gy and cli­mate pro­gram, which aims to im­prove en­er­gy ef­fi­cien­cy for all in­dus­tri­al and com­mer­cial op­er­a­tions and use re­new­able en­er­gy sources where avail­able and fea­si­ble,” the com­pa­ny stat­ed.

No­var­tis tout­ed what it’s al­ready do­ing to pre­serve the en­vi­ron­ment, in­clud­ing se­ques­ter­ing car­bon through forestry projects in Colom­bia, Mali, Chi­na and Ar­genti­na. It plant­ed 800 hectares of trees at the San­to Domin­go Es­tate in Ar­genti­na in 2007, then added 2,250 hectares in the fol­low­ing three years. By 2040, the com­pa­ny ex­pects to col­lect up to 2 mil­lion tons of car­bon diox­ide equiv­a­lents through the project. It al­so boast­ed of its Texas wind farm, and says it has sim­i­lar plans to achieve green en­er­gy in Eu­rope.

“Af­ter the suc­cess­ful com­ple­tion of a re­new­able pow­er pur­chase agree­ment in the US that achieved car­bon neu­tral­i­ty in that mar­ket for pro­cured elec­tric­i­ty we are now ac­tive­ly pur­su­ing a pan-Eu­ro­pean pow­er pur­chase agree­ment that will achieve the same, de­car­boniz­ing our pur­chased elec­tric­i­ty in one of our largest re­gions of op­er­a­tions and elim­i­nat­ing tran­si­tion risk as­so­ci­at­ed with car­bon pric­ing,” No­var­tis’ CDP cli­mate change in­for­ma­tion re­quest states.

The an­nounce­ment comes about 7 months af­ter UK-based As­traZeneca com­mit­ted to achiev­ing neg­a­tive car­bon emis­sions across its val­ue chain by 2030. The com­pa­ny will in­vest up to $1 bil­lion in its “Am­bi­tion Ze­ro Car­bon” strat­e­gy, which in­cludes us­ing re­new­able en­er­gy for pow­er and heat, and switch­ing to a 100% elec­tric ve­hi­cle fleet five years ahead of sched­ule.

“Cli­mate change is an ur­gent threat to pub­lic health, the en­vi­ron­ment and the sus­tain­abil­i­ty of the glob­al econ­o­my. Since 2015, we have re­duced our car­bon emis­sions from op­er­a­tions by al­most a third and our wa­ter con­sump­tion by al­most one fifth,” As­traZeneca CEO Pas­cal So­ri­ot said in a state­ment.

New research shows how generic drug companies can successfully market a limited number of approved indications for a brand name drug, prior to coming to market for all of the indications. But several recent court decisions have created a layer of uncertainty around these so-called “skinny” labels.

While courts have generally allowed generic manufacturers to use their statutorily permitted skinny-label approvals, last summer, a federal circuit court found that Teva Pharmaceuticals was liable for inducing prescribers and patients to infringe GlaxoSmithKline’s patents through advertising and marketing practices that suggested Teva’s generic, with its skinny label, could be employed for the patented uses.

The Centers for Medicare and Medicaid Services on Tuesday said it will only pay for Biogen’s Aduhelm and other FDA-approved anti-amyloid monoclonal antibodies for Alzheimer’s disease under CMS-approved randomized controlled trials.

The draft national coverage decision, which insurers nationwide are likely to follow, makes clear that CMS will be looking for randomized controlled trials that “demonstrate a clinically meaningful benefit in cognition and function.” That will be a tough task for Biogen, which previously showed conflicting benefits from past Aduhelm trials that were initially cut short due to futility and then resurrected for the accelerated approval.

The co-owner of a Florida-based clinical research site pleaded guilty to lying to an FDA investigator during a 2017 inspection, revealing that she falsely portrayed part of a GlaxoSmithKline pediatric asthma study as legitimate, when in fact she knew that certain data had been falsified, the Department of Justice said Wednesday.

Three other employees — Yvelice Villaman Bencosme, Lisett Raventos and Maytee Lledo — previously pleaded guilty and were sentenced in connection with falsifying data associated with the trial at the CRO Unlimited Medical Research.